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SUMMARY 
The electrocardiograms were compared in two groups of schizophrenic patients (Experimental group 
N=43, Control group N=60). The selected cases were given 4 mg of Trifluoperazine daily by IM route for five 
days. A 12 lead ECG was taken thrice in each case. A statistical analysis of the data showed definite changes in 
many of the ECG variables. Comparatively more changes were noticed in the experimental group and in patients 
beyond the age of 45 years. 
Introduction 
The antipsychotic drugs (APD) are 
known to produce various side-effects. 
The cardiovascular (CVS) side-effects are 
more common (Descotes et al. 1979) and 
are likely to be lethal. These side-effects 
are more likely to be missed. APD pro-
duce myocardial depressant effects which 
may result in prolonged conduction times, 
(Yoon et al. 1979) delayed refractory 
periods, diminished cell-membrane ionic 
permeability (Landmark 1971 & 1970), de-
creased myocardial contractility (Langer 
1968) and repolarization abnormalities 
(Alvarez-Mena et al. 1973; Thornton and 
Wendkos 1971; Huston et al. 1966; 
Wendkos 1964). These changes usually 
lead to minor cardiotoxicity and elec-
trocardiographic (ECG) abnormalities 
though chronic administration of APD 
may cause cardiomegaly, congestive car-
diac failure, refractory arrhythmias (Ale-
xander 1968) and even cardiomyopathy 
(Inoue 1979). 
The APD-induced minor cardiotoxic-
ity usually results in "benign" or "non-
specific" ECG changes like prolongation 
of QT duration (Huston et al. 1966; 
Watanabe et al. 1973), T wave changes 
(Wendkos et al. 1969),appearance of U-
wave (Ban et al. 1964), ST depression 
(Watanabe et al. 1973) and slight change in 
PR interval (Backman et al. 1964). These 
changes are seen even in patients without 
CVS pathology and they usually disappear 
with discontinuation of APD therapy 
(Huston et al. 1966). However, sometimes 
they may induce serious and potentially 
fatal arrhythmias e.g. occurrence of ven-
tricular ectopics in a patient with pro-
longed QT duration may lead to R-on-T 
phenomenon resulting in ventricular 
tachycardia and fibrillation. In some in-
stances the myocardial effects may com-
bine with neuroleptic induced hypoten-
sion, autonomic and respiratory distur-
bances to cause sudden death. 
The need to study the ECG correlates 
of longstanding APD therapy is obvious. 
Curiously enough there are not many ECG 
studies in patients on long term APD 
therapy (Fakuda et al. 1982; Schwalbe et 
al. 1978). Most of the studies reported are 
retrospective in nature with methodological 
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flaws e.g. multidrug regimen and non-
homogenous sample in respect to age, 
diagnosis and duration of illness. 
The present work was conducted with 
the aims- 1. To study the ECG changes in 
chronic schizophernic patients and 2. to 
compare the ECG changes in chronic 
schizophrenic patients on prolonged antip-
sychotic medication with patients not on 
prolonged drug therapy. 
Material and Methods 
Sample: 103 ambulatory, chronic 
schizophrenic in-patients of C.I.P., Ran-
chi were included in the study. They were 
divided into an experimental group of 43 
patients (23 male and 20 female), and a 
control group of 60 patients (44 male and 
16 females). Patients in experimental 
group were hospitalized continuously for 
two years or more, whereas control group 
patients were recently admitted in the hos-
pital. 
Selection Criteria: 
- Age 18-60 years. 
- A diagnosis of schizophrenia by Re-
search Diagnostic Criteria (Spitzer et al. 
1978). 
- A schizophrenic illness of at least 2 years 
duration 
- The patients with evidence of heart dis-
ease, either according to history or phys-
ical examinations were excluded. 
Procedure 
After preliminary screening, an in-
formed consent was obtained and possible 
side-effects of the drug was explained to 
the patients. A thorough clinical examina-
tion including pulse, blood pressure and 
cardiac status was done in every case. A 
routine hemogram and a random blood 
sugar estimation were also done, before 
the first ECG was taken. The patients in 
experimental group were kept without 
antipsychotic drugs for at least 2 weeks to 
obtain a baseline ECG. No patient on in-
tramuscular fluphenazine decanoate was 
included in the study for the reason of a 
long washout period required. The pa-
tients included in the control group were 
only those cases who were on no drugs for 
2 weeks or more before their hospitaliza-
tion. 
In selected patients, two milligrams of 
trifluoperazine via intramuscular route 
were given twice a day for five days. No 
other drug was given to the patients during 
this five days period. A routine, 12 lead 
ECG in supine position, was taken thrice 
in each case. The first ECG was a baseline 
record taken during drug-free period i.e. 
just before the patient was put on in-
tramuscular trifluoperazine. The second 
ECG was taken within 24-36 hours of start-
ing the medication, and the last ECG was 
taken on the 5th day of the drug therapy. 
In each ECG a long strip was taken in the 
standard lead II and VI in order to look for 
any rhythm variation. Each ECG was 
analysed for its various components, re-
polarization abnormalities and ar-
rhythmias. Repolarization abnormalities 
were graded using the criteria of Wendkos 
(1967). 
Results 
Different ECG variables were com-
pared within and between groups using 
mean, standard deviation, 't' test and per-
centage values. The results showed that 
88.37% of the patients in the experimental 
group had ECG changes in comparison to 
66.67% of the control group. The most 
common change noticed in the experimen-
tal group was the prolonged QTC interval 
(88.37%). ST depression was found in the 
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Ectopic beats were seen more in the ex-
perimental group (4.65%) than the control 
group (1.67%). Tachycardia and 
bradycardia were comparatively more 
common in the control group (Table 1). 
Table 1 
Percentage Value of ECG changes 
ECG changes  Expt.Gr. Control Gr. 
(N=43) (N=60) 
Tachycardia 
Bradycardia 
ST depression 
T-wave abnormalities 
QTC prolongation 
U-wave changes 
Ectopic beats 
16.28 
25.58 
23.26 
79.07 
88.37 
39.53 
4.65 
31.67 
31.67 
-
65.00 
66.67 
36.67 
1.67 
A consistently gradual decrease in the 
mean heart rate was noticed in both the 
groups in their successive ECG recordings. 
A statistically significant difference at .05 
level has been found between the first and 
the third tracing and between the second 
and third tracing of the experimental 
group, though no such significant differ-
ence was noticed between the first and sec-
ond tracing in the same group. A similar 
trend of decreasing mean heart rate was 
found in the control group also but it was 
not as conspicuous as in the experimental 
group (Table 2). 
A gradual prolongation of the mean 
QTC duration (0.41" to 0.456" in males and 
0.40" to 0.465" in females) was seen in the 
successive ECG tracing. The mean QTC 
duration was found to be increased in the 
1st ECG of the experimental groups in 
comparison to control group. The differ-
ence was significant at .01 level. This dif-
ference was not significant by the time 3rd 
ECG record was taken. 
Intra-group comparison in male sub-
jects revealed statistically significant dif-
ference at .01 level between 1st and 2nd 
and 3rd ECG record of experimental 
group. The difference between 2nd and 
3rd ECG was not found to be significant. 
However, in female subjects of the experi-
mental group, this difference among the 
ECG tracing was not significant. 
In both male and female control 
groups significant difference at .001 level 
was found between 1st and 2nd and 1st and 
3rd ECG records. The difference between 
2nd and 3rd ECG record of male group 
was significant at .02 level whereas in 
female group this was not found to be sig-
nificant (Table 3). 
When the ECG changes were corre-
lated with age and duration of illness, a 
gradual rise in the ECG abnormalities 
were found with advancing age and 
Table 2 
Mean, Standard deviation and't' value of Heart Rate (Per minute) 
ECG. 
Recordings 
1st 
2nd 
3rd 
Y 1 vs. 2 
't* 1 vs. 3 
't'2vs.3 
Experimental Group 
Male 
Mean S.D. 
74.22 ± 15.79 
71.83 ± 11.26 
67.69 ± 8.29 
1.01 N.S. 
2.18 P<.05 
2.12 P<.05 
Female 
Mean S.D. 
88.3 ± 18.94 
85.7 ± 13.91 
80.25 ± 12.67 
.82 N.SD. 
2.36 P<.05 
2.5 P<.05 
t 
2.56 P<.02 
3.48 P<.01 
3.69 P<.01 
Control 
Male 
Mean S.D. 
78.70 + 15.83 
77.73 ± 16.16 
73.20 ± 14.76 
.36 N.S. 
2.1 P<.05 
1.78 P<.10 
Group 
Female 
Mean S.D. 
89 ± 11.99 
85.13 ± 18.21 
84.69 ± 10.73 
.86 N.S. 
1.77 P<.10 
.11 N.S. 
t 
2.63 P< 
1.39 NS 
3.24 P< 
.02 
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Table 3 
Mean, Standard deviation and 't' value of Heart Rate Per Q-TC 
(Prolonged Q-TC 0.42" in male and 0.43" in female) 
Male  Female 
Experimental 
Group 
Control 
Group 
Experimental Control 
Group Group 
1st 
2nd 
3rd 
V 1 vs. 2 
V 1 vs. 3 
V 1 vs. 3 
Mean S.D. 
.435 ± .03 
.455 ± .02 
.456 ± .02 
3.5 p<.0t 
3.88 P<.01 
.51 N.S. 
Mean S.D. 
.41 ± .01 
.44 ± .02 
.45 ± .02 
7.12p<.001 
9.16 P<.001 
2.6 P<.01 
t 
3.49 p<.01 
2.48 p<.02 
.99 N.S. 
Mean S.D. 
.415 ±.03 
.46 ± .02 
.46 ± .02 
.90 N.S. 
.78 N.S. 
Mean S.D. 
.40 ± .02 
.45 ± .01 
.465 ± .02 
8.31 p<.001 
8.41 P<.001 
t 
5.92 p<.01 
1.77 p<.10 
.66 N.S. 
chronicity of the illness. A statistically sig-
nificant difference at .01 level was found 
between the age range of 31-45 years and 
46-60 years. A similar trend (but at .10 
level) was noticed between the patients 
having illness for less than 10 years and 
those having it for more than 10 years 
(Table 4). 
Table 4 
ECG changes Correlated with age and duration of ill-
ness 
Age 
Dura-
tion of 
illness 
Range 
15-30 years 
30-45 years 
46-60 years 
5 years 
<10yrs 
>10yrs 
Percentage of 
patients with 
ECG changes 
35 
50 
88.39 
40.91 
50 
76.74 
CR 
3.24 
p<.01 
1.98 
p<.10 
Disscussion 
A significant percentage of patients 
having ECG changes in both the groups 
clearly shows the CVS side-effects of 
APD. The ECG changes were found to be 
comparatively more in patients on pro-
longed APD therapy. Longterm APD 
medication has been found to cause more 
ECG abnormalities (Schwalbe et al. 1978 
and Watanahe et al. 1973). 
A gradual diminution in global heart 
rate was an interesting observation. A 
similar finding has not been reported in 
any of the studies though Appleton et al. 
(1980) mentioned a decrease in the heart 
rate irr individual cases due to APD. 
A very large number of patients 
showed QTC prolongation. It was seen 
more in chronic schizophrenic in-patients 
who were on APD for a long time. Even 
their basal record (after a washout period of 
two weeks) showed a prolonged QTC dura-
tion. Similar findings were reported by 
Watanabe et al. (1973) and Schwalbe et al. 
(1978). The increase in the QTC duration 
was much more marked in the first 24-36 
hours and it slowed down by the fifth day. 
Other workers have reported similar finding 
(Nizamie et al. 1985; Yoon et al. 1979; 
Langslet 1969; Landmark et al. 1969). The 
gradual diminution in prolongation of QTC 
duration may be a physiological adaptation 
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Presence of ST segment depression in 
the experimental group only may be due to 
prolonged APD therapy. Watanabe et al. 
(1973) reported ST depression to be the 
most common finding in a group of schizop-
hrenic patients receiving long-term 
phenothiazines. 
T-wave abnormality in both the 
groups showed that long term medication 
as well as exposure to APD for a short 
period, both can interfere with myocardial 
repolarization (Schwalbe et al. 1978; 
Wendkos et al. 1969). 
Prolongation of myocardial repolari-
zation may also lead to de novo appear-
ance or prominence of existing U-wave 
(Banetal. 1964;Backmanetal. 1964). It is 
believed that phenothiazines shift potas-
sium to the intracellular compartment (Al-
verez-Mena et al. 1973). This results in 
hypokalemia and consequent upright, 
prominent U-wave (Goldman 1982). Oral 
potassium supplement reverses the re-
polarization abnormalities secondary to 
APD (Alverez-Mena et al. 1973). APD 
cause both atrial and ventricular ectopics 
(Langslet 1969; Landmark et al. 1969) al-
beit infrequently (Tatibouet et al. 1980). 
In the present study few cases developed 
ectopic beats. Presence of ectopics in male 
patients only is an interesting observation. 
There is some hormonal basis for it, since 
women have been found to show signific-
antly less cardiac dysrrhythmia than men 
(Van Diji et al. 1981). 
A very large number of patients 
(88.89%) beyond the age of 45 years showed 
ECG changes. It suggested increased sus-
ceptibility to cardiotoxicity in older patients. 
Similarly, patients with longer duration of 
illness had more of ECG changes. These 
findings suggest that a patient with longer 
duration of illness who is in his 40's should 
be given APD more cautiously. 
In conclusion, it may be said that a sig-
nificant number of patients on APD de-
velop features of cardiotoxicity which be-
comes more evident in middle aged pa-
tients with long duration of illness and on 
long term APD therapy. 
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